Logo image of BME

BLACKROCK HEALTH SCIENCES (BME) Stock Overview

USA - NYSE:BME - US09250W1071

38.3 USD
+0.16 (+0.42%)
Last: 10/24/2025, 3:43:45 PM
Fundamental Rating

2

Taking everything into account, BME scores 2 out of 10 in our fundamental rating. BME was compared to 0 industry peers in the Unkown industry. BME has a bad profitability rating. Also its financial health evaluation is rather negative. BME does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

BME had negative earnings in the past year.
In the past year BME had a positive cash flow from operations.
BME had positive earnings in 4 of the past 5 years.
In multiple years BME reported negative operating cash flow during the last 5 years.
BME Yearly Net Income VS EBIT VS OCF VS FCFBME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA -4.83%
ROE -5.03%
ROIC 0.16%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
BME Yearly ROA, ROE, ROICBME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15

1.3 Margins

BME's Profit Margin has declined in the last couple of years.
BME's Operating Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.92%
PM (TTM) N/A
GM 100%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
BME Yearly Profit, Operating, Gross MarginsBME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

3

2. Health

2.1 Basic Checks

BME has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BME has been increased compared to 5 years ago.
The debt/assets ratio for BME is higher compared to a year ago.
BME Yearly Shares OutstandingBME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BME Yearly Total Debt VS Total AssetsBME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 14.44 indicates that BME is not in any danger for bankruptcy at the moment.
The Debt to FCF ratio of BME is 0.02, which is an excellent value as it means it would take BME, only 0.02 years of fcf income to pay off all of its debts.
A Debt/Equity ratio of 0.00 indicates that BME is not too dependend on debt financing.
Although BME does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Altman-Z 14.44
ROIC/WACCN/A
WACCN/A
BME Yearly LT Debt VS Equity VS FCFBME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

BME has a Current Ratio of 0.10. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
BME has a Quick Ratio of 0.10. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
BME Yearly Current Assets VS Current LiabilitesBME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

1

3. Growth

3.1 Past

The earnings per share for BME have decreased strongly by -150.26% in the last year.
Measured over the past years, BME shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.80% on average per year.
BME shows a decrease in Revenue. In the last year, the revenue decreased by -6.58%.
BME shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.91% yearly.
EPS 1Y (TTM)-150.26%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-108.48%
Revenue 1Y (TTM)-6.58%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-2.46%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BME Yearly Revenue VS EstimatesBME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

0

4. Valuation

4.1 Price/Earnings Ratio

BME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BME Price Earnings VS Forward Price EarningsBME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 6.03
EV/EBITDA N/A
BME Per share dataBME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

5

5. Dividend

5.1 Amount

BME has a Yearly Dividend Yield of 7.65%, which is a nice return.
Compared to an average S&P500 Dividend Yield of 2.34, BME pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.65%

5.2 History

The dividend of BME has a limited annual growth rate of 3.39%.
BME has been paying a dividend for at least 10 years, so it has a reliable track record.
BME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.39%
Div Incr Years1
Div Non Decr Years10
BME Yearly Dividends per shareBME Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

The earnings of BME are negative and hence is the payout ratio. BME will probably not be able to sustain this dividend level.
DP-148.67%
EPS Next 2YN/A
EPS Next 3YN/A
BME Yearly Income VS Free CF VS DividendBME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

BLACKROCK HEALTH SCIENCES

NYSE:BME (10/24/2025, 3:43:45 PM)

38.3

+0.16 (+0.42%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)09-03 2025-09-03
Earnings (Next)03-05 2026-03-05
Inst Owners23.81%
Inst Owner Change-0.01%
Ins Owners0%
Ins Owner Change0%
Market Cap494.84M
Revenue(TTM)7.47M
Net Income(TTM)-25560000
Analysts0
Price TargetN/A
Short Float %0.14%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 7.65%
Yearly Dividend2.67
Dividend Growth(5Y)3.39%
DP-148.67%
Div Incr Years1
Div Non Decr Years10
Ex-Date10-15 2025-10-15 (0.2621)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 66.24
P/FCF 6.03
P/OCF 6.03
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)6.35
FCFY16.57%
OCF(TTM)6.35
OCFY16.57%
SpS0.58
BVpS39.32
TBVpS39.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.83%
ROE -5.03%
ROCE 0.2%
ROIC 0.16%
ROICexc 0.16%
ROICexgc 0.16%
OM 13.92%
PM (TTM) N/A
GM 100%
FCFM 1097.72%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
ROICexc(3y)0.2%
ROICexc(5y)0.12%
ROICexgc(3y)0.2%
ROICexgc(5y)0.12%
ROCE(3y)0.25%
ROCE(5y)0.16%
ROICexgc growth 3Y199.74%
ROICexgc growth 5Y4.01%
ROICexc growth 3Y199.74%
ROICexc growth 5Y4.01%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z 14.44
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-150.26%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-108.48%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.58%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-2.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.46%
EBIT growth 3Y185.41%
EBIT growth 5Y8.1%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y432.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y432.12%
OCF growth 3YN/A
OCF growth 5YN/A

BLACKROCK HEALTH SCIENCES / BME FAQ

What does BME do?

Blackrock Health Sciences Trust is a US-based company operating in industry. The company is headquartered in Wilmington, Delaware. The company went IPO on 2005-03-29. BlackRock Health Sciences Trust (the Trust) is a closed-end management investment company. The Trust investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and by employing a strategy of writing (selling) call and put options. The Trust invests in a portfolio of sectors, which include pharma, biotech and life sciences; healthcare equipment and services; semiconductors & semiconductor equipment; financial services, and others. BlackRock Advisors, LLC acts as the investment adviser of the Trust.


What is the stock price of BLACKROCK HEALTH SCIENCES today?

The current stock price of BME is 38.3 USD. The price increased by 0.42% in the last trading session.


What is the ChartMill rating of BLACKROCK HEALTH SCIENCES stock?

BME has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.